KellieSpragueMD(She/Her)

Hematology • Portland, ME

Hematologic Oncology

Director, Hematologic Malignancies Program

Join to view full profile

Dr. Sprague is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sprague's full profile

Already have an account?

Office
MaineHealth Cancer Care/Maine Medical Center
Suite 2
Portland, ME 04106
Phone+1 207-661-0200

Summary

Dr. Kellie Sprague is a hematologist in Portland, ME and is affiliated with Maine Medical Center. She received her medical degree from University of Vermont College of Medicine and has been in practice 26 years. She specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myeloproliferative disorders, myelodysplasia, and myelofibrosis.

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
Tufts Medical CenterResidency, Internal Medicine, 1991 - 1994
University of Vermont College of MedicineClass of 1991

Certifications & Licensure

ME State Medical License 2020 - 2026
NH State Medical License 2024 - 2024
MA State Medical License 1997 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Boston Magazine Castle Connolly, 2010-2020

Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies Start of enrollment: 2006 Jul 01
Completed
Phase 2
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
Completed
Phase 2
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

123 citations
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation
Uma Narayanasami, Rajani Kanteti, Julie Morelli, Alanna Klekar, Asma Al-Olama
Blood. 2001-10-01
23 citations
A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT.
Andreas K. Klein, Kenneth B. Miller, Kellie Sprague, Jeffrey A. DesJardin, David R. Snydman
Bone Marrow Transplantation. 2011-02-01
165 citations
Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-contr...
Drew J. Winston, Jo Anne H. Young, Vinod Pullarkat, Genovefa A. Papanicolaou, Ravi Vij
Blood. 2008-06-01

Journal Articles

Clinicopathologic Characteristics of Secondary Squamous Cell Carcinoma of Head and Neck in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation for Hematolo...
Kenneth B Miller, Kellie A Sprague, Chakra P Chaulagain, Esha Kaul, Andreas K Klein, Janet Cowan, Nature
A randomized, double-blinded, placebo-controlled trial of valacyclovir prophylaxis to prevent herpes zoster recurrence from months 4 to 24 months after BMT
Klein A, Miller KB, Sprague K, Desjardin JA, Snydman DR, Bone Marrow Transplantation
Prospective Study of Extracoporeal Photopheresis in Steroid-refractory or Steroid-resistant Extensive Chronic Graft-versus-Host-Disease: Analysis of Response & Surviva...
Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, Chan G, Stiffer K. Miller KB, Bone Marrow Transplantation
Immunomodulatory Effects of Extracoporeal Photopheresis in Patients with Extensive Chronic Graft-Versus-Host-Disease
Alcindor T, Gorgun G, Miller KB, Roberts TF, Sprague K, Schenkein DP, Foss FM, Blood
Randomized Trial of Filgrastim versus Chemotherapy and Filgrastim Mobilization of Hematopoietic Progenitor Cells for Rescue in Autologous Transplantation
Narayanasami U, Kanteri R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Connor C, Bermkan E, Erban JK, Sprague KA, Miller KB, Schenkein DP, Blood
Hyperleukocytosis during Induction Therapy with Arsenic Trioxide for Relased Acute Promyelocytic Leukemia associated with Central Nervous System Infarction
Robert TF, Sprague K, Schenkein DP, Relais V, Miller KB, Blood
Join now to see all

Books/Book Chapters

5 Minute Clinical Consults
Chapter: Thrombotic Thrombocytopenia Purpura
Sprague KA, Curtin C

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
American Society of Transplantation and Cellular Therapy
Member